Terms: = Ovarian cancer AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825
19588 results:
1. Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer.
Wang Y; Chen X; Chen Q; Liu T; Wu Y; Huang L; Chen Y
J Cell Mol Med; 2024 May; 28(9):e18371. PubMed ID: 38686496
[TBL] [Abstract] [Full Text] [Related]
2. Patient-Derived Xenograft Models for ovarian cancer.
Tran TM; Ho GY; Chu S
Methods Mol Biol; 2024; 2806():187-196. PubMed ID: 38676803
[TBL] [Abstract] [Full Text] [Related]
3. Effects of Resveratrol on In Vivo ovarian cancer Cells Implanted on the Chorioallantoic Membrane (CAM) of a Chicken Embryo Model.
Chitcholtan K; Singh M; Tino A; Garrill A; Sykes P
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673959
[TBL] [Abstract] [Full Text] [Related]
4. Synthesis of Estrone Heterodimers and Evaluation of Their In Vitro Antiproliferative Activity.
Bózsity N; Nagy V; Szabó J; Pálházi B; Kele Z; Resch V; Paragi G; Zupkó I; Minorics R; Mernyák E
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673860
[TBL] [Abstract] [Full Text] [Related]
5. Cellular Imaging and Time-Domain FLIM Studies of Meso-Tetraphenylporphine Disulfonate as a Photosensitising Agent in 2D and 3D Models.
Balukova A; Bokea K; Barber PR; Ameer-Beg SM; MacRobert AJ; Yaghini E
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673807
[TBL] [Abstract] [Full Text] [Related]
6. Using Portuguese BRCA pathogenic variation as a model to study the impact of human admixture on human health.
Andaluz S; Zhao B; Sinha S; Lagniton PNP; Costa DA; Ding X; Brito M; Wang SM
BMC Genomics; 2024 Apr; 25(1):416. PubMed ID: 38671360
[TBL] [Abstract] [Full Text] [Related]
7.
Ghosh A; Jaaback K; Boulton A; Wong-Brown M; Raymond S; Dutta P; Bowden NA; Ghosh A
Cells; 2024 Apr; 13(8):. PubMed ID: 38667331
[TBL] [Abstract] [Full Text] [Related]
8. Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation.
Perri G; Vilas Boas VG; Nogueira MRS; Mello Júnior EJF; Coelho AL; Posadas EM; Hogaboam C; Cavassani KA; Campanelli AP
Cancer Immunol Immunother; 2024 Apr; 73(6):110. PubMed ID: 38662248
[TBL] [Abstract] [Full Text] [Related]
9. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
10. Effects of 5-fluorouracil, thymoquinone, and mammary stem cells' exosomes on
Abdelfattah-Hassan A; Ibrahim D; Saleh AA; Kishawy ATY; Mohamed RHA; Khater SI
Open Vet J; 2024 Jan; 14(1):525-533. PubMed ID: 38633189
[TBL] [Abstract] [Full Text] [Related]
11. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous ovarian cancer.
Flores-Colón M; Rivera-Serrano M; Reyes-Burgos VG; Rolón JG; Pérez-Santiago J; Marcos-Martínez MJ; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612604
[TBL] [Abstract] [Full Text] [Related]
12. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
13. Construction and analysis of competitive endogenous RNA networks and prognostic models associated with ovarian cancer based on the exoRBase database.
Chen Z; Wang C; Ding J; Yu T; Li N; Ye C
PLoS One; 2024; 19(4):e0291149. PubMed ID: 38603733
[TBL] [Abstract] [Full Text] [Related]
14. Spatiotemporal transcriptomic changes of human ovarian aging and the regulatory role of FOXP1.
Wu M; Tang W; Chen Y; Xue L; Dai J; Li Y; Zhu X; Wu C; Xiong J; Zhang J; Wu T; Zhou S; Chen D; Sun C; Yu J; Li H; Guo Y; Huang Y; Zhu Q; Wei S; Zhou Z; Wu M; Li Y; Xiang T; Qiao H; Wang S
Nat Aging; 2024 Apr; 4(4):527-545. PubMed ID: 38594460
[TBL] [Abstract] [Full Text] [Related]
15. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
16. Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
Martincuks A; Zhang C; Austria T; Li YJ; Huang R; Lugo Santiago N; Kohut A; Zhao Q; Borrero RM; Shen B; Cristea M; Wang EW; Song M; Rodriguez-Rodriguez L; Yu H
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580335
[TBL] [Abstract] [Full Text] [Related]
17. Bio synthesis, comprehensive characterization, and multifaceted therapeutic applications of BSA-Resveratrol coated platinum nanoparticles.
Faisal S; Tariq MH; Abdullah ; Zafar S; Un Nisa Z; Ullah R; Ur Rahman A; Bari A; Ullah K; Khan RU
Sci Rep; 2024 Apr; 14(1):7875. PubMed ID: 38570564
[TBL] [Abstract] [Full Text] [Related]
18. MATN2 overexpression suppresses tumor growth in ovarian cancer via PTEN/PI3K/AKT pathway.
Liu J; Zhang J; Zhang Y; Yang B; Liu H; Chen Y
Funct Integr Genomics; 2024 Apr; 24(2):71. PubMed ID: 38568332
[TBL] [Abstract] [Full Text] [Related]
19. LncRNA SNHG12 promotes cell proliferation and inhibits apoptosis of granulosa cells in polycystic ovarian syndrome by sponging miR-129 and miR-125b.
Xuan F; Jin R; Zhou W; Ye Y; Ren Y; Lu J; Chen A
J Ovarian Res; 2024 Apr; 17(1):72. PubMed ID: 38566229
[TBL] [Abstract] [Full Text] [Related]
20. Novel (±)-
Jurin M; Stepanić V; Bojanić K; Vadlja D; Kontrec D; Dražić T; Roje M
Acta Pharm; 2024 Mar; 74(1):37-59. PubMed ID: 38554382
[TBL] [Abstract] [Full Text] [Related]
[Next]
